 Immune therapy with tumor antigenic peptides is generally quite well tolerated. However, immune activation is often only weak or even undetectable, and clinical responses supposedly corresponding to protective immunity are unfortunately infrequent. Further progress is required to improve the vaccines, with the goal to increase the strength of immune activation. 